Literature DB >> 21506779

Weak cytotoxic activity of miltefosine against clinical isolates of Acanthamoeba spp.

M Mrva1, M Garajová, M Lukáč, F Ondriska.   

Abstract

Hexadecylphosphocholine (miltefosine) is an anticancer drug active in vitro against various protozoan parasites, and recently used for the treatment of disseminated Acanthamoeba infection. In the present study, we present results of weak cytotoxic activity of this potential amoebicidal agent for 2 of 3 clinical isolates of Acanthamoeba spp. Although the inhibition effect for all tested concentrations was apparent, and showed 100% eradication of trophozoites of Acanthamoeba castellanii strain at a concentration of 62.5 µM after 24 hr, the strains Acanthamoeba sp. and Acanthamoeba lugdunensis exhibited low sensitivity to hexadecylphosphocholine, even in high concentrations. The determined minimal trophocidal concentrations were 250 µM for Acanthamoeba sp. and 500 µM for A. lugdunensis after 24 hr of exposure. Although hexadecylphosphocholine is a potential agent for treatment of Acanthamoeba keratitis and systemic infections, in clinical practice the possible insusceptibility of the amoebic strain should be considered for optimizing therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21506779     DOI: 10.1645/GE-2669.1

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  5 in total

1.  Investigation of the in vitro cysticidal activity of miltefosine against Acanthamoeba spp.

Authors:  Malin Chao; Thaksaporn Thongseesuksai; Thidarut Boonmars; Porntip Laummaunwai
Journal:  J Parasit Dis       Date:  2020-02-17

2.  Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium.

Authors:  Kirti Megha; Megha Sharma; Chayan Sharma; Amit Gupta; Rakesh Sehgal; Sumeeta Khurana
Journal:  Eye (Lond)       Date:  2021-09-21       Impact factor: 4.456

3.  Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs.

Authors:  Brian Shing; Mina Balen; James H McKerrow; Anjan Debnath
Journal:  Expert Rev Anti Infect Ther       Date:  2021-05-19       Impact factor: 5.091

Review 4.  Drug Discovery against Acanthamoeba Infections: Present Knowledge and Unmet Needs.

Authors:  Hany M Elsheikha; Ruqaiyyah Siddiqui; Naveed Ahmed Khan
Journal:  Pathogens       Date:  2020-05-22

5.  Fluorescent labeling of Acanthamoeba assessed in situ from corneal sectioned microscopy.

Authors:  Susana Marcos; Jose Requejo-Isidro; Jesus Merayo-Lloves; A Ulises Acuña; Valentin Hornillos; Eugenia Carrillo; Pablo Pérez-Merino; Susana Del Olmo-Aguado; Carmen Del Aguila; Francisco Amat-Guerri; Luis Rivas
Journal:  Biomed Opt Express       Date:  2012-09-12       Impact factor: 3.732

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.